These data demonstrate that multidrug resistant B-cell lymphomas maintain sensitivity to EZH2 inhibitors, and that GSK126 induced cytotoxicity is independent of EZH2 histone methyltransferase activity. This evidence concerns the gene PRDM9 and B-cell non-Hodgkin lymphoma.